Jason Zhang | Chief Executive Officer and Co-Founder
Zipcode Bio

Jason Zhang, Chief Executive Officer and Co-Founder, Zipcode Bio

As the CEO and Founder of Zipcode Bio, Dr. Jason Zhang is leading a paradigm shift at the crossroads of chemistry, immunology, and pharmaceuticals. His collaborative efforts with Nobel Laureate Dr. Drew Weissman and Prof. Virgil Percec in co-founding the startup, Zipcode Bio, reflect a strategic fusion of expertise. Dr. Zhang's multidisciplinary background, featuring Ph.Ds in Chemistry and Immunology, coupled with executive education at Berkeley Haas, forms the bedrock for transformative innovation. Drawing on over 15 years of corporate expertise cultivated in influential roles at Novartis, Sanofi, Wave Life Sciences, Luye Life Sciences, and RVAC Medicines, Dr. Zhang has adeptly navigated the complexities of the pharmaceutical landscape, leaving an indelible mark. A prolific author with 50+ articles and patents, Dr. Zhang's commitment to advancing scientific knowledge is underscored by his strategic leadership as the former Chief Scientific Officer in two companies. His previous fundraising prowess securing over $170 million and collaborations with prestigious institutions like Oxford, UPenn, and industry giants such as Pfizer, exemplify his influential network. Steering over 10 projects into IND and clinical developments, Dr. Zhang's research spans diverse drug modalities offering invaluable insights into the dynamic landscape of healthcare and drug development. At the forefront of pioneering advancements, Dr. Jason Zhang stands poised to shape the future of the industry.

Appearances:



Pre-Congress Workshops - Monday 1st April @ 10:00

RNA - From vaccines to therapeutics

How are we improving our understanding of RNA technology for next generation vaccines? How will RNA transform therapeutics and cancer treatment?

10:00 Chair opening remarks

10:10 mRNA vaccines of the future: Bridging the Knowledge GapsDr Sudha Chivukula, AVP, Head of Discovery Biology, mRNA Centre of Excellence, Sanofi

10:25 Beyond respiratory vaccines   Dr Jacqueline Miller, SVP, Therapeutic Area Head - Infectious Disease Development, Moderna

10:45 Individualized mRNA vaccines Ruben Rizzi, Senior Vice President Global Regulatory Affairs, BioNtech

11:00 Reserved

11:15 Analytical challenges in characterization of multivalent mRNA vaccinesDr Gautam Sanyal, Principal Consultant and Founder, Vaccine Analytics, LLC

11:30 RNABL: A Novel RNA Delivery Platform for Therapeutic ApplicationsDr Micheal Breen, Scientist, Tiba Biotech

11:45 From a preventive vaccine to a therapeutic vaccineDr Jason Zhang, CEO and Co-Founder, ZipCode Bio

12:00 – 1:00 Panel: Beyond prophylactic vaccines: the future of RNA therapeutics

  • What is the potential for RNA use in therapeutics?
  • Cancer, immunotherapy, gene editing etc.
  • What gaps remain to successfully utilize the potential of RNA beyond vaccines?

Moderator: Anna Rose Welch, Editorial and Community Director, Advancing RNA, Life Science Connect Dr Gilles Besin, CSO, Orbital Therapeutics Dr Gopi Shanker, CSO, Beam Therapeutics Dr Andrew Geall, Chief Development Officer, Replicate Bioscience

last published: 26/Feb/24 13:16 GMT

back to speakers